About
Team
Pipeline
OPN-2853
OPN-6602
OPN-FMRP
OPN-7486
OPN-9840
OPN-9627
Patients
News
Press Releases
Publications
& Posters
Careers
Contact
General information
info@opnabio.com
Investor inquiries
bd@opnabio.com
Media and BD inquiries
bd@opnabio.com
2018
Select PROGRAMS
All Programs
OPN-2853
(9)
OPN-51107
(17)
OPN-6602
(3)
OPN-7486
(5)
OPN-TEAD
(1)
Select Dates
All Dates
2024
(4)
2023
(3)
2022
(1)
2021
(3)
2020
(3)
2019
(7)
2018
(4)
2017
(3)
2016
(2)
2015
(3)
August 23, 2018
Publication
ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition
AUTHORS
Roberts, et al
Programs
OPN-7486
https://doi.org/10.1182/blood-2018-05-849554
June 6, 2018
Publication
Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the antitumor efficacy of immune checkpoint blockade
AUTHORS
Duffy, et al
Programs
OPN-7486
https://www.jimmunol.org/content/200/1_Supplement/122.15/tab-article-info
May 20, 2018
Poster
Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors
AUTHORS
Patnaik, et al
Programs
OPN-2853
Download PDF
January 31, 2018
Publication
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
AUTHORS
Ozer , et al
Programs
OPN-51107
https://doi.org/10.1158/2159-8290.CD-17-0902